Ligand Pharma (LGND) Tops Q1 EPS by 29c, Offers FY Guidance

Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.41, $0.29 better than the analyst estimate of $1.12. Revenue for the quarter came in at $55.2 million versus the consensus estimate of $62.85 million.

GUIDANCE:

Ligand Pharma sees 2021 EPS of $6.15, versus the consensus of $6.17. Ligand Pharma sees 2021 revenue of $291 million, versus the consensus of $292 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Nucor projects Q3 2026 earnings above prior year, below estimates
• Lumentum shares rise on analyst upgrades, AI demand outlook